Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

mRNA litigation: Who’s winning, who’s filing, and what’s next
Biotech
mRNA litigation: Who’s winning, who’s filing, and what’s next
As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.   25 March 2026
Dechert boosts litigation bench with partner duo
Careers
Dechert boosts litigation bench with partner duo
Two senior hires from a rival firm bring litigation expertise across life sciences and tech disputes.   25 March 2026
UK court deals blow to Spanish pharma’s SPC bid for contraceptive
Europe
UK court deals blow to Spanish pharma’s SPC bid for contraceptive
The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.   24 March 2026
Pharma
Part II: The race to replace semaglutide heats up
With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?   23 March 2026
Asia
Part I: Ozempic goes generic as Novo’s key patent expires
As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.   20 March 2026
Pharma
Sandoz strikes fresh biosimilar deal with South Korean biotech
The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.   19 March 2026
Careers
US firm boosts patent bench with Desmarais hire
A new partner hire at the firm brings rare depth across both the ITC and district courts in technology and life sciences.   18 March 2026
Americas
J&J unit targets former employee over alleged mass data theft
Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.   17 March 2026
Americas
Natera and a rival draw the line under five-year fight
The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.   27 February 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.   26 February 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.